-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] On July 28, CSPC announced that its subsidiary CSPC Jushi Bio has reached an agreement with Elevation Oncology, an American biopharmaceutical company, which obtained CSPC Jushi Bio-antibody-conjugated drug (ADC) SYSA1801 in Exclusive license agreement for development and commercialization outside of Greater China (including Mainland China, Hong Kong, Macau and Taiwa.
According to the agreement, the transaction is valued at nearly $2 billion, including an upfront payment of $27 million, potential development and regulatory milestone payments of up to $148 million, and potential sales milestone payments of up to $02 billi.
CSPC Jushi Bio is also entitled to receive a sales commission of up to a double-digit percentage based on the annual net sales of the product in the regi.
CSPC Jushi Bio will retain all rights to this product in Greater Chi.
The industry believes that in recent years, the journey of domestic innovative drugs to overseas has continued to open, and with the successful commercialization of zanubrutinib in overseas markets in 2021, innovative drugs are poised to go overseas, and there is a vast world to .
Among them, license out (Chinese pharmaceutical companies license their overseas rights or global rights of their products to pharmaceutical companies represented by European and American multinational pharmaceutical companies, and obtain down payment and milestone fees) cases are also gradually increasi.
In addition to CSPC, in May this year, Kelun Pharmaceuticals also authorized the biomacromolecule tumor project A to Merck for commercial development outside Chi.
The cumulative milestone payment will not exceed 363 billion US dollars, and according to the agreement of both parties percentage of net sal.
This is also the largest external authorization transaction of Kelun Pharmaceuticals so f.
On July 26, Kelun Pharmaceutical announced that Kelun Biotech and Merck had signed a licensing agreement again, and Kelun Biotech will license its early clinical biological macromolecular tumor project B with independent intellectual property rights to Merck on a global sca.
Research, development, manufacturing and commercialization within the compa.
In May, Jimin Trust Group also announced that its subsidiary Shanghai Jiyu Pharmaceutical Technology .
, L.
has reached an exclusive cooperation agreement with ORION CORPORATION (hereinafter referred to as "ORION.
According to the agreement, ORION will obtain the development, production and commercialization rights of the new non-opioid analgesic drug (JMKX000623) independently developed by Shanghai Jiyu outside the Greater China regi.
The relevant rights and interests of the drug in the Greater China region are still owned by Jimin Tru.
At the same time, ORION will pay Shanghai Jiyu an upfront payment of 15 million euros, and pay the corresponding development and commercialization milestones when the milestones agreed in the agreement are reach.
In addition, Shanghai Jiyu will also receive a commercialization commission of 8%-15% of the net sales of the cooperative products in the cooperative ar.
The domestic competition for innovative drug research and development is fierce, and innovative drugs have become the choice of many pharmaceutical companies to go overse.
According to relevant statistics, in 2015, domestic companies only carried out clinical trials in 14 overseas countries, with only 48 projec.
By 2019, Chinese pharmaceutical companies have deployed overseas clinical trials in more than 50 countries, accumulative projec.
The total number is over 34Analysts pointed out that at a time when new medical reforms continue to deepen, industrial technologies are added iteratively, professional talents continue to emerge, and capital support is increasingly strengthened, Chinese pharmaceutical companies are facing opportunities and challenges from all directions, like sailing against the current, and must be driven by innovation to continuously improve their busine.
The layout accelerates the internationalization proce.
For innovative pharmaceutical companies, license out is an important component of reven.
According to the industry, in recent years, license out is getting better and better, and it will be the mainstream mode of going overseas in the futu.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
According to the agreement, the transaction is valued at nearly $2 billion, including an upfront payment of $27 million, potential development and regulatory milestone payments of up to $148 million, and potential sales milestone payments of up to $02 billi.
CSPC Jushi Bio is also entitled to receive a sales commission of up to a double-digit percentage based on the annual net sales of the product in the regi.
CSPC Jushi Bio will retain all rights to this product in Greater Chi.
The industry believes that in recent years, the journey of domestic innovative drugs to overseas has continued to open, and with the successful commercialization of zanubrutinib in overseas markets in 2021, innovative drugs are poised to go overseas, and there is a vast world to .
Among them, license out (Chinese pharmaceutical companies license their overseas rights or global rights of their products to pharmaceutical companies represented by European and American multinational pharmaceutical companies, and obtain down payment and milestone fees) cases are also gradually increasi.
In addition to CSPC, in May this year, Kelun Pharmaceuticals also authorized the biomacromolecule tumor project A to Merck for commercial development outside Chi.
The cumulative milestone payment will not exceed 363 billion US dollars, and according to the agreement of both parties percentage of net sal.
This is also the largest external authorization transaction of Kelun Pharmaceuticals so f.
On July 26, Kelun Pharmaceutical announced that Kelun Biotech and Merck had signed a licensing agreement again, and Kelun Biotech will license its early clinical biological macromolecular tumor project B with independent intellectual property rights to Merck on a global sca.
Research, development, manufacturing and commercialization within the compa.
In May, Jimin Trust Group also announced that its subsidiary Shanghai Jiyu Pharmaceutical Technology .
, L.
has reached an exclusive cooperation agreement with ORION CORPORATION (hereinafter referred to as "ORION.
According to the agreement, ORION will obtain the development, production and commercialization rights of the new non-opioid analgesic drug (JMKX000623) independently developed by Shanghai Jiyu outside the Greater China regi.
The relevant rights and interests of the drug in the Greater China region are still owned by Jimin Tru.
At the same time, ORION will pay Shanghai Jiyu an upfront payment of 15 million euros, and pay the corresponding development and commercialization milestones when the milestones agreed in the agreement are reach.
In addition, Shanghai Jiyu will also receive a commercialization commission of 8%-15% of the net sales of the cooperative products in the cooperative ar.
The domestic competition for innovative drug research and development is fierce, and innovative drugs have become the choice of many pharmaceutical companies to go overse.
According to relevant statistics, in 2015, domestic companies only carried out clinical trials in 14 overseas countries, with only 48 projec.
By 2019, Chinese pharmaceutical companies have deployed overseas clinical trials in more than 50 countries, accumulative projec.
The total number is over 34Analysts pointed out that at a time when new medical reforms continue to deepen, industrial technologies are added iteratively, professional talents continue to emerge, and capital support is increasingly strengthened, Chinese pharmaceutical companies are facing opportunities and challenges from all directions, like sailing against the current, and must be driven by innovation to continuously improve their busine.
The layout accelerates the internationalization proce.
For innovative pharmaceutical companies, license out is an important component of reven.
According to the industry, in recent years, license out is getting better and better, and it will be the mainstream mode of going overseas in the futu.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
